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Background: SARS-CoV nsp10 binds and stimulates both the nsp14 and nsp16 activities.
Results: We mapped the nsp10 surface interacting with nsp14 and demonstrated that this surface plays a critical role in
SARS-CoV replication.
Conclusion: The core interaction domain of nsp10 is essential for SARS-CoV replication.
Significance: This nsp10 core represents an attractive target for antiviral drug development against various pathogenic
coronaviruses.
The RNA-synthesizingmachinery of the severe acute respira-
tory syndromeCoronavirus (SARS-CoV) is composedof 16non-
structural proteins (nsp1–16) encoded by ORF1a/1b. The 148-
amino acid nsp10 subunit contains two zinc fingers and is
known to interact with both nsp14 and nsp16, stimulating their
respective 3-5 exoribonuclease and 2-O-methyltransferase
activities. Using alanine-scanningmutagenesis, in cellulo biolu-
minescence resonance energy transfer experiments, and in vitro
pulldown assays, we have now identified the key residues on the
nsp10 surface that interact with nsp14. The functional conse-
quences of mutations introduced at these positions were first
evaluated biochemically by monitoring nsp14 exoribonuclease
activity. Disruption of the nsp10-nsp14 interaction abrogated
the nsp10-driven activation of the nsp14 exoribonuclease. We
further showed that the nsp10 surface interacting with nsp14
overlaps with the surface involved in the nsp10-mediated acti-
vation of nsp16 2-O-methyltransferase activity, suggesting that
nsp10 is a major regulator of SARS-CoV replicase function. In
linewith this notion, reverse genetics experiments supported an
essential role of the nsp10 surface that interacts with nsp14 in
SARS-CoV replication, as several mutations that abolished the
interaction in vitro yielded a replication-negative viral pheno-
type. In contrast, mutants in which the nsp10-nsp16 interaction
was disturbed proved to be crippled but viable. These experi-
ments imply that the nsp10 surface that interacts with nsp14
and nsp16 and possibly other subunits of the viral replication
complex may be a target for the development of antiviral com-
pounds against pathogenic coronaviruses.
Viruses in the order Nidovirales, which includes the Corona-
viridae, Arteriviridae, Roniviridae, and (proposed) Mesoniviri-
dae families, possess the largest RNA genomes known to date
(1, 2). Coronaviruses (CoVs)9 are respiratory and enteric patho-
gens of humans and domesticated animals and also appear to be
omnipresent in wildlife, in particular in bats and rodents (3–5).
The capability to cross species barriers appears to be a wide-
spread CoV feature, and all endemic human CoVs are thought
to have been transmitted fromanimal hosts at somepoint in the
past. CoVs can cause life-threatening zoonotic infections, and
the emergence in humans, less than a decade apart, of CoVs
causing severe acute respiratory syndrome (SARS) (6) andMid-
dle East respiratory syndrome (MERS) (7, 8) emphasizes the
significant pandemic potential of members of this virus family.
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SARS-CoV presumably emerged from bats in China in 2002,
spread around the globe in a fewmonths, and resulted in8000
registered cases with a fatality rate of 10% (3, 9, 10). MERS-
CoV emerged in the Middle East in 2012 and has thus far
resulted in800 laboratory-confirmed cases with a fatality rate
around 35% (7, 8, 11, 12).
The SARS-CoV genome is a single-stranded, positive-sense
RNA of 29.7 kb, which is 5-capped and 3-polyadenylated.
After virus entry, genome translation initiates a complex gene
expression program (13, 14) that is regulated at the transla-
tional, post-translational, and transcriptional levels. Open
reading frames (ORFs) 1a and 1b, which occupy the 5-proxi-
mal two-thirds of the genome, are translated directly from the
genome to yield two large polyprotein (pp) precursors called
pp1a and pp1ab. The latter is derived from extension of pp1a
with theORF1b-encoded sequence after a1 ribosomal frame-
shift near the 3 end ofORF1a, which gives rise to a fixed ratio of
pp1a over pp1ab synthesis (15–30% ribosomal frameshift effi-
ciency reported; Refs 15–17). The two replicase polyproteins
are cleaved into a total of 16 functional proteins (see Fig. 1)
called nonstructural protein 1 (nsp1) to nsp16. Viral RNA syn-
thesis entails genome replication, which proceeds via a full-
length minus-strand RNA, and the synthesis of an extensive
nested set of subgenomic mRNAs, each from their own subge-
nome-length minus-stranded template (13, 18–20). Sub-
genomic mRNAs are used to express structural and accessory
proteins encoded in the 3-proximal third of the genome (see
Fig. 1).
After replicase polyprotein cleavage, the SARS-CoV nsps
assemble into a multienzyme replication-transcription com-
plex that is associated with membrane structures derived from
the modification of the host cell endoplasmic reticulum (21,
22). Although the functions of some CoV nsps have remained
elusive thus far (e.g. nsp2 and nsp9), enzymatic activities have
been attributed to many others. Some of these are commonly
found in the RNA virus world (e.g. protease, helicase, and RNA
polymerase functions), whereas others are rare or even unique,
including e.g. an endoribonuclease of unknown function in
nsp15 and the nsp14 exoribonuclease, which has been impli-
cated in a primitive form of proofreading that enhances the
fidelity of CoV RNA synthesis (for more details please refer to
reviews in Refs. 14 and 23).
The CoV genome also encodes proteins required for the for-
mation and modification of the cap structure present at the 5
end of all coronaviral mRNAs. In eukaryotic cells most mRNAs
of invading viruses and the host itself are modified by the addi-
tion of such a cap, which protects from degradation by 5-3
exoribonucleases, ensures efficient translation, and in the case
of viral mRNAs helps to prevent recognition by the host innate
immune system (24–27). In the eukaryotic cell, the cap is added
co-transcriptionally in the nucleus by the sequential activity of
four enzymes: (i) an RNA triphosphatase, (ii) a guanylyltrans-
ferase, (iii) an N7-methyltransferase (MTase), and (iv) a 2-O-
MTase yielding a so-called cap-1 structure (7MeGpppN2-O-Me)
(24, 28). The biological importance of the latter structure is
underlined by the fact that numerous viruses have evolved
strategies to secure the presence of cap-1 at the 5 terminus of
their mRNAs (for a review, see Ref. 29).
Positive-stranded RNA viruses, like SARS-CoV, replicate in
the cytoplasm and are, therefore, presumed not to have access
to the host cell capping machinery. Nevertheless, the 5 end of
CoVmRNAs is thought to carry a type-1 cap (30–32), which is
produced by the concerted action of several viral enzymes (33,
34). As in many other positive-strand RNA viruses, an RNA
triphosphatase activity is embedded in the RNA helicase car-
ried by nsp13 and is likely to mediate the first step of viral cap
synthesis (35). The guanylyltransferase activity involved inCoV
cap synthesis has remained elusive thus far. In contrast, two
CoV methyltransferase activities were identified and assigned
to the C-terminal domain of nsp14 ((N7-guanine)-methyl-
transferase) (33, 34) and nsp16 (2-O-MTase) (36).We recently
demonstrated that the in vitro activity of the SARS-CoV nsp16
2-O-MTase depends on an interactionwith nsp10. The nsp10-
nsp16 complex exhibits a potent MTase activity specifically
converting cap-0 (7MeGpppN) into cap-1 structures (34).
Nsp10 is 148 residues long, contains two zinc fingers, and is
overexpressed relative to nsp14 and nsp16 as it is encoded in
ORF1a. Although its structure was solved almost 10 years ago
(Fig. 1), no enzymatic function was identified or proposed for
the protein (37, 38). Together with other replicase subunits,
nsp10, nsp14, and nsp16 were implicated in the formation of
the CoV replication-transcription complex (39), a process that
is likely based on a large repertoire of specific interactions of
nspswith other nsps andwith viral RNA sequences. The nsp10-
nsp16 interaction was characterized biochemically and struc-
turally to decipher the molecular basis of nsp10 function in
activating the nsp16-mediated 2-O-MTase activity. Several
key residues for the nsp10-nsp16 interaction were identified,
and these findings were subsequently supported by the crystal
structure of the complex (40, 41). The recent observation that
2-O-methylation of the RNA cap may be mandatory to avoid
or delay viral RNA recognition by innate immune sensors high-
lights the importance of the nsp10-nsp16 2-O-MTase complex
in CoV-host interplay (42–44).
Using bioinformatics and biochemistry, a 3-5 exoribonu-
clease (ExoN) activity has been identified inCoVnsp14, with its
catalytic residues (DEDD) mapping to the N-terminal part
of the protein (6, 45). Subsequently, an (N7-guanine)-methyl-
transferase activity involved in viral mRNA capping was iden-
tified in the C-terminal domain of the same protein (33, 46).
The nsp14 (N7-guanine)-methyltransferase domain does not
seem to be functionally separable from the ExoN domain (33,
47). A predicted interaction between nsp10 and nsp14 (48, 49)
was recently confirmed in vitro by Bouvet et al. (34, 47) in a
study demonstrating a second regulatory role for SARS-CoV
nsp10. Upon interacting with nsp10, the ExoN activity of nsp14
increased by 35-fold. Using diverse RNA substrates, the
nsp10-nsp14 ExoN activity was shown to specifically degrade
double-stranded (ds) RNAs with a preference for substrates
carrying a single non-hybridized nucleotide at their 3 end. This
study together with the 15–20-fold increased mutation rate
observed for reverse engineered ExoN-deficient nsp14mutants
(50, 51) strongly suggested the involvement of ExoN in a unique
RNA proofreading mechanism allowing CoVs to safeguard the
integrity of their unusually large RNA genome. Interestingly,
nsp10 does not show any effect on nsp14 (N7-guanine)-meth-
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yltransferase activity in vitro (34). Considering the importance
of the nsp10 protein in the regulation of viral enzymatic activ-
ities and replication-transcription complex assembly, it consti-
tutes an attractive target for drug design programs.
In this context we now combined several approaches to map
the nsp10-nsp14 interaction at the molecular level. Using an
extendedmutagenesis approach and by coupling in cellulo bio-
luminescence resonance energy transfer (BRET) studies to in
vitro functional assays, we identified a continuous and specific
nsp10 surface involved in the interaction with nsp14. Key sur-
face residues involved in this interaction were found to control
SARS-CoV nsp14 ExoN activity and also appear to be part of
the nsp10 domain that interacts with nsp16. Thus, nsp10 pos-
sesses overlapping interaction surfaces for the activation of two
important viral enzymes. Reverse genetics experiments target-
ing key residues of this domain revealed that they are indeed
critical for SARS-CoV replication, thus validating this surface
as a potential target for antiviral drug development.
EXPERIMENTAL PROCEDURES
Reagents—All radioactive reagents were purchased from
PerkinElmer Life Sciences. S-Adenosyl-L-methionine was pur-
chased from New England Biolabs.
Plasmids—All cloning experiments were performed using
Gateway technology (Invitrogen). For BRET experiments,
plasmid constructions are described in Lugari et al. (41). The
SARS-CoV nsp10 and nsp14 expression plasmids (pDest14/
His6-nsp10 and pTXB1-nsp14) were described previously (34).
Nsp10 and nsp14 genes were also cloned into a dual-promoter
expression plasmid as described previously (52). In this back-
bone SARS-CoV nsp10 is expressed in fusion with an N-termi-
nal Strep-TagII (named Strep-nsp10), whereas nsp14 is fused to
an N-terminal hexahistidine tag (named nsp14HN). Single
point mutant plasmids were generated by PCR using the
QuikChange site-directedmutagenesis kit (Stratagene) accord-
ing to the manufacturer’s instructions.
Cell Culture—HEK 293T cells were grown in accordance
with ATCC recommendations in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum, 2 mM L-glu-
tamine, 50 units/ml penicillin, and 50 g/ml streptomycin.
Vero-E6 cells (ATCC: CRL-1586) were cultured in Eagle’s min-
imal essential medium (EMEM; Lonza) with 8% fetal calf serum
(PAA) and antibiotics. BHK-Tet-SARS-N cells (53) were cul-
tured in Eagle’s minimum essential medium with 8% fetal calf
serum (PAA), antibiotics, and 100 g/ml of G418.
BRET Assays—Cells in 6-well plates were transfected using
FuGENE 6 transfection reagent (Roche Applied Science)
according to the manufacturer’s protocol. Cells were plated
with 300,000 cells per well, 8 h before transfection. Transfec-
tions were made with 300 ng of pNRLuc-nsp14 vector and var-
ious amounts of pEYFP-nsp10 vectors (50–100-300–600-900
ng) complemented with pUC19 vector for a total of 1.5 g of
DNA transfected per well. Cells were then incubated at 37 °C,
5% CO2 for 48 h prior to the BRET assays. BRET assays were
performed in living cells according to Lugari et al. (41). In each
experiment transfections of pNRLuc-nsp14 alone or plus
pEYFP were performed as controls. Coelenterazine H (Tebu-
Bio) was added on cells at a 5 M final concentration, and cells
were incubated for 20min at room temperature before reading.
BRET measurements were performed at 25 °C by sequentially
integrating luminescence signals at 480 and 530 nm for 1 s. The
BRET ratio is defined as: [(emission at 530 nm) (emission at
485 nm) Cf]/(emission at 485 nm), where Cf corresponds to
(emission at 530 nm)/(emission at 485 nm) for theRenilla lucif-
erase (Rluc) fusion protein expressed alone under the same
experimental conditions. All experiments were performed at
least three times, and BRET signals were normalized according
FIGURE 1.Schematic representationof SARS-CoVgenomeandnsp10 structure.Nsp10 (orange) and nsp14/16 (pink) are highlighted. The structural (green)
and accessory (purple) protein genes are expressed from a nested set of subgenomic mRNAs. The schematic of the nsp10 structure (PDB code 2FYG) was
generated using PyMOL software. Zinc ions are shown as green spheres, and residues forming the two nsp10 zinc fingers are labeled and depicted as brown
sticks.
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to the fluorescence signals of nsp10-EYFP mutants compared
with wild type.
Antibodies—Anti-GFP antibodies (a mix of clones 7.1 and
13.1 was used) were purchased from Roche Applied Science.
Anti-Renilla luciferase antibodies (mAb4400 and mAb4410)
were purchased fromChemicon. Secondary antibodies coupled
to horseradish peroxidase were purchased from Dako. Alexa-
conjugated antibodies for immunostaining are from Jackson
ImmunoResearch laboratories.
Expression and Purification of SARS-CoV nsp10 and nsp14
Proteins—Expression and purification of His6-nsp10 from
Escherichia coli transformed with pDest14/His6-nsp10 and
untagged nsp14 from E. coli carrying pTXB1-nsp14 were per-
formed as previously described (34, 47). SARS-CoV nsp10-
nsp14 co-expression was performed as described for nsp10-
nsp16 in Debarnot et al. (52).
RNA Synthesis and Purification—Synthetic RNA H4 was
purchased from Jena Bioscience (HPLC grade). H4 RNA was
radiolabeled using polynucleotide kinase (New England
Biolabs) and [-32P]ATP according to the manufacturer’s
instructions.
Exonuclease Assay—The reactions were performed as
described by Bouvet et al. (47). Briefly, nsp10 and nsp14 were
incubated in a 4:1molecular ratio with radiolabeled RNA (oligo
H4, 5-UGACGGCCCGGAAAACCGGGCC-3) (47). After 30
min the reaction was stopped. The reaction products were sep-
arated on denaturing polyacrylamide gels and visualized using
phosphorimaging (Fluorescent ImageAnalyzer FLA3000; Fuji).
The relative ExoN activity was quantified using Image Gauge
software.
PulldownAssay—For pulldown assays, SARS-CoVnsp10 and
nsp14 were co-expressed in E. coli using a dual promotor
approach. In this system SARS-CoV nsp10 expression is under
control of a tet promoter and produces a protein in fusion with
an N-terminal Strep-TagII, whereas nsp14 is expressed from a
T7 promoter and carries an N-terminal His6 tag. E. coli C41
(DE3) cells (Avidis SA, France) harboring the pLysS plasmid
(Novagen) were transformed with the various expression vec-
tors and grown in 2YT medium containing antibiotics. Protein
expression was induced by adding 50 M isopropyl 1-thio--D-
galactopyranoside and 200 g/liter anhydrotetracycline, then
cells were incubated for 16 h at 24 °C. Bacterial cell pellets were
frozen and resuspended in lysis buffer (50 mM HEPES, pH 7.5,
500 mM NaCl, 5 mM MgSO4) supplemented with 1 mM PMSF,
10g/ml DNase I, and 0.5%Triton X-100. After sonication and
clarification, proteins were purified by chromatography with
Strep-Tactin-Sepharose (IBA GmbH, Göttingen, Germany).
After 3washes in high salt buffer (1MNaCl) and 3washes in low
salt buffer (500 mMNaCl), bound proteins were eluted with 2.5
mM D-desthiobiotin in binding buffer. The purified proteins
were analyzed and quantified by capillary electrophoresis (Cal-
iper LabChip, PerkinElmer Life Sciences).
SARS-CoV Reverse Genetics—Using “en passant recom-
bineering” (recombineering by mutagenesis) (54), mutations in
the nsp10-, nsp14-, and nsp16-coding regions of SARS-CoV
isolate Frankfurt-1 were engineered in prSCV, a pBeloBac11
derivative containing a full-length cDNA copy of the viral
genome (55). The DNA of such BAC clones was linearized with
NotI, extracted with phenol-chloroform, and transcribed with
the mMessage-mMachine T7 (Ambion) using 2 g of DNA
template in a 20-l reaction. Full-length viral RNA was precip-
itatedwith LiCl according to themanufacturer’s protocol, and 6
g was electroporated into 5  106 BHK-Tet-SARS-N cells,
which express the SARS-CoVNprotein after4 h of induction
with 2Mdoxycycline (53). Electroporationwas done using the
AmaxaNucleofector (Lonza), Nucleofector Kit T, and program
T-020 according to the manufacturer’s instructions. Cells were
mixed in a 1:1 ratio with Vero-E6 cells and seeded on coverslips
for immunofluorescence microscopy and for analysis of virus
production. Each mutant was launched twice from indepen-
dently generatedBACclones. All workwith live SARS-CoVwas
performed inside biosafety cabinets in a biosafety level 3 facility
at Leiden University Medical Center.
RT-PCR Analysis of the nsp10, nsp14, and nsp16 Coding
Region—Fresh Vero-E6 cells were infected with harvests taken
at 42 h post transfection, and cells were incubated overnight.
Intracellular RNA was isolated from the infected cells by
using TriPure Isolation Reagent (Roche Applied Science) as
described by the manufacturer’s instructions and amplified by
RT-PCR using random hexamers to prime the RT reaction, and
primers 5-TTGCCTACTATAACAATTCG-3 and 5-GTTA-
TAAATAGTCTCTTCATGTTGG-3 for PCR amplification
of the nsp10-coding region. The nsp14 region was amplified by
using primers 5-GGTTCTGAATATGACTATGTCATATT-
C-3 and 5-CCTGTCCTTCCACTCTACCATC-3; the prim-
ers for amplification of the nsp16-coding region were 5-CTA-
TGCTGAAATTTCATTCATGC-3 and 5-TGGTGCACCG-
GTCAAGGTCACTACC-3. Amplicons were sequenced to
verify the presence of the original mutations and/or putative
(second site) reversions.
In both experiments with mutant nsp10-M44A, no sign of
virus replication was observed at early time points (18–48 h
post transfection) using either immunofluorescence micros-
copy or titration of viral progeny. In one experiment, however,
all cells died from viral infection in a dish used to obtain a 72 h
post-transfection harvest. Thismaterial was used to infect fresh
Vero-E6 cells for RNA isolation and amplification of the nsp10-
coding region by RT-PCR. Sequencing of this product revealed
that the original M44A mutation had been converted into
M44V.
Immunofluorescence Microscopy—To monitor the progres-
sion of SARS-CoV infection, transfected cells on coverslips
werefixedatvarioustimepointsposttransfection.Immunofluo-
rescence assays were done after a previously described protocol
(56) using a rabbit antiserumagainst nsp4 (21) andmAb against
N (kindly provided by Ying Fang, South Dakota State Univer-
sity; Ref. 57). As the expression level of N in BHK-Tet-SARS-N
cells is much lower than the level reached in infected cells, it is
possible to discriminate between SARS-CoV-positive and -neg-
ative cells.
Titration of Virus Progeny andPlaque ReductionAssays—For
plaque assays, Vero-E6 cells seeded in 6-well clusters were
infected with serial 10-fold dilutions (in PBS containing 0.005%
DEAE and 2% FCS) of supernatants from transfected cells. The
inoculum was removed after 1 h at 37 °C and replaced with an
overlay of 1.2% Avicel (FMC BioPolymer) in DMEM supple-
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mented with 50 mM HEPES, 2% FCS. Cells were incubated at
37 °C, and after 3 days cell layers were fixed with 7.4% formal-
dehyde in PBS and stained with crystal violet to visualize
plaques. Titers are expressed in plaque forming units per ml.
Plaque reduction assays were essentially performed as plaque
assays with the following modifications; each well of a 6-well
cluster was infected with the same amount of virus (15–30
plaque forming units per well). Subsequently, the overlays that
were applied contained increasing concentrations of 5-fluoro-
uracil (Sigma), ranging from 0 to 250 M.
RESULTS
Mapping of nsp10 Surface Residues Involved in the Interac-
tion with nsp14—We recently showed that the interaction of
nsp10 with nsp14 induces a 35-fold stimulation of nsp14
ExoN activity (47). This qualitative study pinpointed nsp10 res-
idues involved in this interaction that are also important for the
nsp10-nsp16 interaction regulating SARS-CoV 2-O-MTase
activity (40, 41, 47). To assess the overlap between these inter-
action surfaces, we first tested the impact of nsp10 mutations
on the nsp10-nsp14 interaction using in cellulo BRET assays
(for an overview of BRET strategy and set-up, see Ref. 58).
Nsp10 mutants were fused to the C terminus of enhanced yel-
low fluorescent protein (EYFP), and nsp14 was fused to the C
terminus of RLuc, all placed under the control of the cytomeg-
alovirus promoter. BRET signal was measured in human HEK
293T cells at 48 h after plasmid transfection (Fig. 2A). As the
expression level of EYFP-nsp10mutants was quite variable, the
amount of transfected plasmid DNA for each mutant was
adjusted to achieve comparable protein expression levels (Fig.
2B). The nsp10 mutations selected to be tested in BRET assays
mainly targeted surface residues described in Lugari et al. (41),
and most of them were known to affect or prevent the nsp10-
nsp16 interaction.
Almost all nsp10mutants testedwith BRETwere impaired in
their interaction with nsp14 (relative BRET values below 50%),
suggesting their involvement in the nsp10-nsp14 interaction
(Fig. 2). The K95A mutant, in which the mutation resides out-
side the interaction surface, yielded a BRET value comparable
with that of wild-type nsp10 and could thus be used as a nega-
tive control for the BRET assay. Because most of the mutations
tested concerned surface residues, it is assumed that they donot
alter the three-dimensional structure of the protein as sup-
ported by the 1H,15N heteronuclear single quantum correlation
NMR experiments of Lugari et al. (41). Three mutants, how-
ever, C73R, H83R, and C120R, target residues close to or
involved in the formation of the two zinc fingers of nsp10 (Fig.
1). Replacement of those residues abrogated the interaction
with nsp14 (BRET values between 10 and 20%), probably due to
misfolding of nsp10. We, therefore, discarded those mutants
for further studies. Finally, the Y96F mutant showed a 80%
FIGURE 2. BRET characterization of the interaction of wild-type and mutant nsp10 with nsp14 in mammalian cells. A, BRET interaction assays were
performed inHEK 293T cells after co-transfection of plasmids expressing EYFP-nsp10mutantswith an RLuc-nsp14 expressing plasmids. The experimentswere
performed three times, and the relative interactionof eachmutant is calculated comparedwith the interactionofwild-typensp10withnsp14 (whichwas taken
to be 100%). The BRET signals were further normalized according to the fluorescence signal measured for nsp10-EYFP mutants compared with wild-type
control. B, Western blot analysis confirming similar levels of protein expression for the two interaction partners. Levels of RLuc-nsp14 and EYFP-nsp10 were
determinedusing anti-luciferase and anti-GFP antibodies, respectively. The anti-luciferase antibody also recognized an70-kDahost cell protein,which could
conveniently serve as a loading control for the cell lysates.
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reduction of the nsp10-nsp14 interaction (BRET value of 21
7.9%) as opposed to its stimulation of the nsp10-nsp16 interac-
tion (41).
Reduced nsp10-nsp14 Interaction Correlates with Loss of
nsp14 ExoN Activity—We next performed pulldown assays to
measure the binding efficiency of each nsp10 mutant to nsp14
in vitro (Fig. 3A). Strep-tagged nsp10 and His6-tagged nsp14
were co-expressed in E. coli. Nsp10 was purified using Strep-
Tactin beads, whereas nsp14 was co-purified in a complex that
was subsequently quantitated by capillary electrophoresis. In
the set of residues targeted by mutagenesis, we now included
alanine mutants of residues Phe-19, Asn-40, Lys-43, Leu-45,
Thr-47, Thr-58, Gly-69, His-80, and Lys-87, which surround
the nsp10 surface as defined by BRET assay, and as a negative
control residue Tyr-126, which is positioned on the opposite
side of the nsp10 structure. For most of the nsp10 mutants
tested (20 of 25), nsp14 binding was reduced by at least 50%,
with approximately half of them displaying a complete loss of
nsp14 co-purification. Mutations V42A, L45A, T47A, T58A,
andK87A reduced the relative binding efficiency to50%com-
pared with wild-type nsp10. Finally, for two of the mutants,
N40A and the negative control Y126A, the interaction with
nsp14 was not or only slightly altered in vitro (Fig. 3A).
We next studied the functional importance of the residues
described above for stimulation of the nsp14 ExoN activity. The
capability of mutant nsp10 proteins to modulate the nsp14
ExoN activity was assayed bymeasuring the hydrolysis of radio-
labeled RNA oligonucleotide H4 by (mutant) nsp10 and nsp14.
As described previously, this RNA substrate forms a double-
stranded RNA structure that can be readily degraded by the
nsp10/nsp14 complex (47). Most nsp10 mutants displaying a
reduced affinity for nsp14, as judged by BRET analysis and the
in vitro binding assay, showed reduced stimulation of the nsp14
ExoN activity compared with wild-type nsp10 (Fig. 3B).
The 15 BRET-identified mutations hampering the nsp10-
nsp14 interaction caused a reduction in both in vitro nsp14
binding and ExoN activity (50% in both assays). The
mutagenesis to alanine of residues Thr-47, Thr-58, and Lys-87,
which surround the nsp10 surface as defined by the BRET
study, resulted in a loss of at least 40% of the binding capacity
but did not significantly affect nsp14 ExoN activation. Several
mutants abrogated the nsp10-nsp14 interaction (F19A, M44A,
G69A, R78A, R78G, H80A, K93A, K93E, and Y96A) and
resulted in a relative nsp14 ExoN activity below 30%, suggesting
an important role for these residues in nsp14 recognition. Two
other mutants, K43A and L45A, showing a relative nsp14 bind-
ing of 40%, affected nsp14 ExoN activity less dramatically
(ExoN activity of 62 13 and 55 17% respectively), suggest-
ing a smaller contribution to the nsp10-nsp14 interaction.
Finally, nsp10mutantY126A, used as negative control, does not
seem to be involved in the nsp10-nsp14 interaction, as nsp14
ExoN activity and in vitro binding values were close to 100%.
We also confirmed that inactivation of the nsp14 ExoN active
site (nsp14 catalytic residues Asp-90 and Glu-92 mutated to
alanine), used as negative control, resulted in a complete loss of
exoribonuclease activity in this assay (47).
Nsp14 and nsp16 Bind to the Same Core Interaction Surface
on nsp10—To interpret our results, we mapped the residues
found to be important by BRET assay by in vitro interaction
analysis and by ExoN activity assays on the three-dimensional
FIGURE 3. Effect of nsp10 mutations on nsp10-nsp14 complex formation and on nsp14-ExoN activity in vitro. A, bar graph showing the relative nsp14
binding to each nsp10mutant, as measured by in vitro pulldown assays. Nsp10 was purified by affinity chromatography and analyzed using capillary electro-
phoresis. The amount of nsp14 interacting with nsp10 was then quantified and normalized using nsp10. The binding activities were compared with the
interaction of wild-type nsp10with nsp14, which was arbitrarily set to 100%. B, relative nsp14 ExoN activities in the presence of a panel of nsp10mutants. The
ExoN activity obtained in the presence of wild-type nsp10 was arbitrarily set to 100%. Each experiment was repeated two times independently. Residues
surrounding the nsp10 surface (as defined by BRET assay) that were newly included at this stage of the study are marked with an asterisk.
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structure of nsp10 (PDB code 2FYG (37)) (Fig. 4, A–C, respec-
tively). The three methods clearly define a common nsp10 sur-
face for the interaction with nsp14. Interestingly, it has previ-
ously been shown that (part of) this same nsp10 surface is also
involved in the interaction with nsp16 and that this surface is
well conserved among coronaviruses (41).
To assess the degree of overlap between nsp10 interaction
surface with nsp14 and nsp16, we first mapped the residues
involved in the nsp10-nsp14 interaction identified above to the
three-dimensional structure of nsp10 (Fig. 5A). Using the struc-
ture of the nsp10-nsp16 complex (PDB code 2XYQ (40)), we
alsomapped the nsp10 residues involved in the interactionwith
nsp16. For this purpose, we highlighted all nsp10 residues
within a 5 Å radius of nsp16 (Fig. 5B). The areas corresponding
to the nsp14 and nsp16 binding surfaces were then marked on
the same nsp10 structure model (Fig. 5C). This figure distinctly
highlights the fact that nsp10 interaction surfaces have a sub-
stantial overlap. The surface that interacts with nsp14 seems to
bemore extended than the one involved in the interaction with
nsp16, as residue Phe-19, that is not involved in the nsp10-
nsp16 interaction, plays a critical role in the nsp10-nsp14 inter-
action. In the nsp10 structure, as depicted in Fig. 5C, the nsp14
interaction surface coversmost of the nsp16 interaction surface
and extends toward the upper part of nsp10. Table 1 summa-
rizes the data obtained for the nsp10-nsp14 interaction com-
pared with the data from the previously described nsp10-nsp16
interaction analysis (41).
Nsp10 Residues Involved in the Interaction with nsp14 Are
Essential for SARS-CoV Replication—A selection of nsp10
mutations described above was reverse-engineered into the
SARS-CoV genome using a BAC-based full-length cDNA clone
from which recombinant virus can be launched (55). We chose
to include mutations affecting the nsp10-nsp14 interaction
only (F19A, K43A, and H80A) or targeting both the nsp10-
nsp14 and nsp10-nsp16 interactions (M44A and Y96A). The
Y96Fmutant was also included, because it was shown to have a
stronger in vitro interaction with nsp16 compared with wild-
type nsp10. As additional phenotypic controls, we constructed
mutants with inactivated nsp14 ExoN (D90A/E92A) (50) or
nsp16 2-O-MTase (D130A) (34) activities. In addition, an
nsp10-nsp16 interaction knock-out mutant was made in which
nsp16 residueMet-247, whichwas previously shown to interact
with nsp10 in the crystal structure of the nsp10-nsp16 complex
(40), was substituted by alanine.
Mutant viruses were launched by electroporation of in vitro
transcribed full-length RNA into BHK-Tet-SARS-N cells (53),
which express the viral nucleocapsid protein. These cells can be
transfected efficiently and produce progeny virions but do not
support further viral spread because they lack the ACE2 recep-
tor used by the virus. For this reason transfected cells were
FIGURE 4. Three-dimensional structure of nsp10 highlighting residues involved in the interactionwith nsp14. SARS-CoV nsp10 (PDB code 2FYG (37)) is
depicted in white as a surface representation. A, residues that were found to be involved in interaction between nsp10 and nsp14 by the in vivo BRET assay
(50% effect) are colored in orange. B, residues that were found to be involved in the nsp10-nsp14 interaction according to the in vitro binding capacity
(pulldown) assays (50% effect) are colored in green. C, residues that were found to be involved in the nsp10 and nsp14 interaction on the basis of ExoN
activity (50% reduction) are colored in dark blue. Residues that could be mutated without significantly altering the nsp10-nsp14 interaction or the
ExoN activity (50% effect) are depicted in purple. Residues not tested in BRET experiments compared with other assays are displayed in gray (N/D). All
figures were generated using PyMOL.
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mixed with (SARS-CoV-susceptible) Vero-E6 cells, and the
replication of mutant viruses was studied at different time
points using immunofluorescence microscopy and progeny
virus titration by plaque assays. For each virus mutant, two
independent mutant full-length cDNA clones were generated
and found to yield identical results. The reverse genetics data
are summarized in Table 2, and plaque phenotypes of replica-
tion-competent mutants are shown in Fig. 6.
Our in vivo data fully support the notion that residues in
nsp10 that are involved in the interactionwith nsp14 are impor-
tant for SARS-CoV replication in cell culture: three of the nsp10
mutations that abolished this interaction in vitro (F19A, H80A,
and Y96A) resulted in a non-viable virus phenotype, whereas a
fourth mutation of this type (M44A) pseudo-reverted at a late
time point in one of two experiments (the original M44A
mutation had been changed to valine (M44V) by 72 h post
transfection). TheK43Amutation, which decreased but did not
block the nsp10-nsp14 interaction and nsp14 ExoN activity in
vitro, yielded a crippled viruswith15-fold reduced titers com-
paredwith thewild-type control 24 h post transfection. Plaques
produced by this virus were slightly smaller than wild-type
plaques and more heterogeneous in size compared with the
wild-type virus or other mutants (Fig. 6).
The non-viable and late-reverting phenotypes of several of
the nsp10mutants cannot be attributed solely to a reduction or
lack of ExoN activity asmeasured in vitro (Table 1), as the ExoN
active site mutant nsp14-D90A/E92A, despite being crippled,
was clearly replication competent (Fig. 6; and also previously
reported by Eckerle et al. (50)). The interaction between nsp10
and nsp16 apparently plays a less critical role in basic CoV rep-
lication, as also illustrated by the replication-competent pheno-
type of mutant nsp16-M247A, which displayed a small-plaque
phenotype and gave an 2-log reduced virus titer at 24 h post
transfection. Its plaque phenotype is similar to that of the 2-O-
MTase active site mutant nsp16-D130A, although the virus
titers of the latter mutant were only1 log lower. The replica-
tion-competent but crippled phenotype of the 2-O-MTase
active sitemutant is comparable with that of the corresponding
mutants previously described for SARS-CoV, MHV, and
HCoV-229E (44, 59). It has been postulated that the conversion
FIGURE 5.Comparisonof thensp14andnsp16 interactiondomainson thensp10 surface.A, schematic representationof nsp10 residues that are engaged
in the nsp10-nsp14 interaction. SARS-CoV nsp10 (PDB code 2FYG (37)) is shown as a white surface representation. Residues that significantly affect the
nsp10-nsp14 interaction when mutated are colored in red (50% decrease of BRET values, binding affinity, and ExoN activity). Residues Lys-43 and Leu-45,
which impair thensp10-nsp14 interactionwith a smaller effectwhenmutated (bothbindingaffinity andExoNactivity50%ofwild type), are shown inorange.
B, representation of nsp10 residues involved in the nsp10-nsp16 interaction in the structure of the complex (PDB code 2XYQ (40)). Nsp16 is shown as a
schematic representation, colored in cyan. Nsp10 residues that are present within a 5 Å radius of nsp16 are depicted in yellow. C, schematic representation of
nsp10 functional interacting surface with nsp14 (red rectangle) and nsp16 (dark yellow square, based on Lugari et al. (41)). The structural nsp10-nsp16 interac-
tion surface is depicted as a dashed yellow rectangle on nsp10. The overlapping functional interaction surface is depicted in pale green. All figures were
generated using PyMOL.
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of cap 0 to cap 1 on viral mRNAs plays an important role in
escape from innate immune recognition but is not essential for
viral replication per se. Mutation nsp10-Y96F, which decreased
the interaction of nsp10 with nsp14 and increased its interac-
tionwith nsp16 in vitro, gave rise to virus titers and plaque sizes
similar to those of the wild-type control. These results strongly
suggest that the replication defect of the non-viable nsp10
mutants is not caused by a reduction of the nsp10-based stim-
ulation of either the nsp14 ExoN activity or the nsp16 2O
MTase function. Apparently, the nsp10 core domain plays a
pleiotropic role during virus replication, as also previously
deduced from data obtained in the MHV model (63).
Given the fact that they compromised both the nsp10-nsp14
interaction and the nsp10-mediated stimulation of the nsp14-
ExoN activity in vitro, we investigated the possibility that the
nsp10 mutations K43A and Y96F increased the SARS-CoV
mutation frequency (“mutator phenotype”) in amanner similar
to what has been reported for the nsp14-D90A/E92A ExoN
knock-out mutant (50). To test whether the K43A and Y96F
mutants also display such a phenotype, plaque reduction assays
were performed in the presence of increasing concentrations of
the mutagen 5-fluorouracil (5FU) (60). As previously reported
(60), increased 5FU sensitivity was readily observed, even at the
lowest dose tested (50 M), for the nsp14-D90A/E92A ExoN
knock-out mutant, which was included as a positive control in
this experiment (Fig. 7). However, nsp10 mutants K43A and
Y96F were found to be equally insensitive to the drug as the
wild-type virus. Only at the highest 5FU dose tested (250M), a
TABLE 1
Effects of a variety of nsp10 surfacemutations on the nsp10-nsp14 and nsp10-nsp16 interactions and on ExoN (nsp14) and 2-O-MTase (nsp16)
enzyme activities













WT 100 100 100 100 100 100
F19Ab ND 0 24 4.9 ND 108 92 5.3
N40A ND 105 59 29.4 ND 64 ND
V42A 33 17 50 28 8 12 2.3 1 1 0.2
K43A ND 38 62 12.6 ND 98 84 13.6
M44A 11 9.8 0 21 3.7 8 5.1 0 0 0.1
L45A ND 44 55 17 ND 6 ND
T47A ND 53 102 2,1 ND 66 ND
T58A ND 52 100 2,5 ND 93 ND
A61V 11 4.2 8 17 7 3 5 ND ND
G69A ND 0 21 7.1 ND 92 ND
G70A 19 1.9 8 49 5 31 7.4 50 32 0.8
S72A 22 4.6 26 42 13.6 60 8.6 6 22 1.1
C73R 9 10.6 ND ND 2 0.6 ND ND
R78A 13 15.2 0 23 6.8 9 4.5 10 2 0.1
R78G 28 18 0 23 4.1 35 1.8 6 9 0.3
H80Ab ND 0 26 1.8 ND 78 60 3.1
H83R 17 14.3 ND ND 13 11.3 ND ND
K87A ND 59 78 14.1 ND 98 ND
K93A 19 10.6 0 19 10.4 35 2.2 54 9 1.2
K93E 0 1.8 0 20 11 7 5.8 16 0 0
G94A 17 15.1 31 27 4.7 59 2.4 80 85 1.2
G94D 19 15.8 13 18 0.8 16 4.9 7 0 0.1
K95A 98 16.8 ND ND 80 3.9 83 71 2.6
Y96Ab 5 6.8 0 20 12 30 6.2 6 15 0.6
Y96I 1 7.9 6 45 3.6 12 2.3 3 4 0.4
Y96V 7 11.9 5 13 1.6 20 3.4 0 5 0.1
Y96F 19 10.6 38 33 9.4 123 18 124 163 10
C120R 8 13.5 ND ND 49 2.7 ND ND
Y126A ND 94 101 0.9 ND 99 ND
EYFP 9 3.8 14 2.2
a Taken from Lugari et al. (41) except for residues Phe-19, Lys-43, and His-80, which were added in this study.
b Mutations prohibiting virus replication.
TABLE 2
Reverse genetics phenotypes of SARS-CoVmutants
Nsp Mutant IFAa Virus titerb Plaque phenotype Summary
WT 	 8 107 Wild type Wild-type control
nsp10 F19A  Non-viable
K43A 	 5 106 Intermediate Crippled
M44A  Non-replicating in one experiment; late pseudo-reversion
to M44V in one experiment
H80A  Non-viable
Y96A  Non-viable
Y96F 	 3.108 Wild type Similar to wild-type control
nsp14 D90A/E92A 	 3 104 Small ExoN knockout mutant. Crippled
nsp16 D130A 	 2 106 Small 2-O-MTase knockout mutant. Crippled
M247A 	 2 105 Small No interaction with nsp10. Crippled
a Immunofluorescence assay, t
 10–72 hpt.
b t
 24 h post transfection, plaque forming units/ml.
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slight reduction in plaque size and numbers was observed for
both wild-type virus and nsp10 mutants (Fig. 7). This observa-
tion is inconsistent with the hypothesis that these nsp10
mutants would have a mutator phenotype, which should have
markedly increased their sensitivity to a mutagen-like 5FU.
DISCUSSION
SARS-CoV nsp14 ExoN activity was recently shown to be
strongly stimulated by the presence of its interaction partner
nsp10 (47). This feature is likely to be highly relevant for the
unique RNA proofreading mechanism that is thought to allow
coronaviruses to reliably replicate their long RNA genome (60).
Accordingly, the replacement of ExoN catalytic residues cre-
ates a mutator phenotype that may in the long run threaten
CoV genetic stability and survival (51, 61).
In this study we identified nsp10 residues involved in the
interaction with nsp14. BRET methodology, considered as one
of the most versatile techniques to study the dynamics of pro-
tein-protein interactions in living cells (62) as well as in vitro
pulldown and enzymatic assays allowed the mapping of key
residues involved in the formation of the nsp10-nsp14 complex
and the nsp10-driven stimulation of the ExoN activity (Figs. 2
and 3). Interestingly, a large majority of the mutants for which
the nsp10-nsp14 interaction was disrupted lost their nsp14
ExoN-activating potential, revealing the critical nature of this
interaction for ExoN activity.
The nsp10 surface deduced to be involved in the nsp10-
nsp14 interaction is conserved across all four genera of the
Coronaviridae subfamily (Fig. 8) (41) and overlaps with the
nsp10-nsp16 interaction surface previously described (Fig. 5;
Refs. 40 and 41). Nsp10 molecules may thus act as a platform
that recruits nsp14 or nsp16 to the replication-transcription
complex to either boost nsp14 ExoN activity or to switch on
nsp16 2-O-MTase activity. Although the overlapping interac-
tion surfaces suggest an exclusive interaction of nsp10 with
either nsp14 or nsp16, the protein is produced at amuch higher
rate due to the fact that, unlike nsp14 and nsp16, it is encoded in
ORF1a, just upstream of the ORF1a/1b ribosomal frameshift
site (6, 19, 63). Even though little is known about the relative
turnover of CoV nsps in general and although nsp10 may have
additional binding partners that remain to be identified, it is fair
to assume that nsp10 levels in infected cells are substantially
higher than those of nsp14 and nsp16, implying that the latter
two proteins would not necessarily be competing to bind nsp10
(16). Thus, nsp10-nsp14 and nsp10-nsp16 complexes may
coexist, possibly as part of larger nsp assemblies engaged in
different steps of viral RNA synthesis.
One nsp10 residue, Tyr-96, is of particular interest. The aro-
matic nature of Tyr-96 plays a crucial role in the nsp10-nsp16
interaction and in the activation of the nsp16 2-O-MTase
activity (41). This residue is specific for SARS-CoVnsp10 and is
a phenylalanine inmost otherCoronavirushomologues (Fig. 7).
As the nsp10Y96Fmutation resulted in an enhanced binding to
nsp16 correlating with an increased 2-O-MTase activity, resi-
due Tyr-96 was hypothesized to fine-tune the strength of
the interaction between nsp10 and nsp16 (41). However, the
underlying mechanism could not be clearly defined at the
molecular level, not even using the structure of the nsp10-
nsp16 complex (40). In this study we show that Tyr-96 is
involved in the interaction with nsp14 and that the nsp10 Y96F
mutation interferes with nsp14 binding and decreases ExoN
activity in vitro. This may explain why a tyrosine residue has
been selected in the course of SARS-CoV evolution, whereas a
phenylalanine has been preferred at this position in other CoVs
to balance the relative affinities of nsp10 for nsp14 and nsp16.
Nevertheless, in reverse genetics experiments the phenotype of
the nsp10 Y96F mutant virus was found to be similar to that of
the wild-type virus, indicating that the presence of a phenylala-
nine residue at this position does not strongly affect viral repli-
cation in the type of short term cell culture experiments
included in this study.
Because complete inactivation of the CoV nsp14 ExoN func-
tion yields a crippled but replicating virus (Refs. 50 and 51 and
confirmed in this study), it was highly surprising that several
nsp10 mutations that disrupt the nsp10-nsp14 interaction
proved to be lethal. Clearly, the non-viable phenotype of these
mutants cannot be explained by the loss of nsp14 ExoN activity
alone, which raises important questions about the functionality
of nsp10 or the nsp10-nsp14 complex in CoV replication.
Nsp14 is a bifunctional enzyme, and its interaction with nsp10
may also influence its critical (N7-guanine)-methyltransferase
activity, although no positive or negative influence of nsp10 on
this activity was observed in in vitro assays (34). Alternatively,
nsp10 or the nsp10-nsp14 complex may have additional yet
unknown functions that are vital for CoV replication. Previ-
ously, based on an MHV study, an indirect role for nsp10 in
proteolytic processing of replicase polyproteins and viral RNA
synthesis was proposed (64, 65). It is conceivable that the non-
viable phenotype of several SARS-CoV nsp10 mutants in the
present study could be attributed to critically influencing one or
more of these as yet poorly defined additional nsp10 functions.
Many of the SARS-CoV nsp10 residues found to affect the
nsp10-nsp14 interaction and viral replication (Gly-69, Gly-70,
Ser-72,His-80, andTyr-96) correspond to residues that localize
within the core of nsp10, as previously defined by Donaldson
FIGURE 6. Plaque morphology of viable SARS-CoV nsp10, nsp14, and
nsp16 mutants. Small-plaque phenotypes were observed for mutants
nsp14-D90A/E92A, nsp16-D130A, andnsp16-M247A, an intermediateplaque
size for mutant nsp10-K43A, whereas the plaque size of mutant nsp10-Y96F
was similar to that of the wild-type control.
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FIGURE 7. Lack of 5-fluorouracil sensitivity of SARS-CoV mutants nsp10-K43A and nsp10-Y96F suggests they do not exhibit a mutator phenotype.
Plaque reduction assays were performed in the presence of increasing concentrations of 5-fluorouracil. Eachwell was infectedwith the same amount of virus,
afterwhich cell layerswere overlaidwith a semi-solidmediumcontaining the indicated increasing concentrations of 5FU. Cell layerswere incubated for 3 days,
fixed, and stained to reveal plaque formation. Like the wild-type virus, nsp10 mutants K43A and Y96F were insensitive to 5FU up to a dose of 250 M. On the
other hand, plaque size andnumber formutant nsp14-D90A/E92A (the ExoNknock-outmutant known toexhibit amutator phenotype)were strongly reduced
even at the lowest 5FU concentration tested.
FIGURE 8. Conservation of the nsp10 sequence across the Coronaviridae subfamily. Alignment of nsp10 sequences from a representative set of Corona-
virinae subfamily viruses including members of each of the four genera (Alpha-, Beta-, Gamma-, and Deltacoronavirus). Residues that are conserved in all
sequences and whose replacement is lethal to SARS-CoV and MHV (Phe-19, Met-44, Gly-69, and Ser-72) are boxed in blue and indicated by triangles. Residues
that are conserved in80% of the sequences and whose replacement is lethal to SARS-CoV (His-80 and Tyr-96) are labeled in blue and indicated by asterisks.
Sequences were aligned using the ESPript program (67). National Center for Biotechnology Information (NCBI) accession numbers for replicase polyprotein
sequences including nsp10 are: SARS-CoV, AY345988; MERS-CoV, JX869059; HCoV-HKU1, AY884001; MHV, AY700211; BtCoV-HKU5, bat Coronavirus HKU5–1
(EF065509); HCoV-229E, NC_002645; HCoV-NL63, DQ445911; FcoV, feline Coronavirus (DQ010921); IBV, avian infectious bronchitis virus (NC_001451); BWCoV-
SW1, beluga whale Coronavirus SW1 (EU111742); ACoV-HKU11, bulbul Coronavirus HKU11-796 (FJ376620); ACoV-HKU13, munia Coronavirus HKU13-3514
(NC_011550); ACoV-HKU12, thrush Coronavirus HKU12-600 (NC_011549).
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et al. (64) forMHVnsp10. This core does not appear to tolerate
mutations (64), and the non-viable phenotype of some of the
MHV mutants tested by Donaldson et al. (64) again seems to
reflect the importance of the nsp10-nsp14 interaction surface
in coronaviruses. For instance, conserved residues Gly-69, Gly-
70, and Ser-72 were targeted for MHV and were all found to be
critical for virus replication, in line with the data from the in
vitro interaction studies presented here for SARS-CoV nsp10.
Still, the non-viable phenotypes could also be explained by
alternative scenarios, like the nsp10 surface being involved in
another function that is critical for coronaviruses replication.
The available data lead us to propose that specific “hot spot”
residues (Phe-19, Met-44, Gly-69, Ser-72, His-80, and Tyr-96)
within and around the nsp10 core can be targeted to disrupt
nsp10-nsp14 interactions and inhibit nsp14 ExoN activity
and/or other nsp10 functions, potentially interfering with CoV
replication. Strikingly, those residues are highly conserved
across coronaviruses, including the recently emerged and
potentially life-threateningMERS-CoV (Fig. 8). Considering its
importance for virus replication, highlighted by this and other
studies, nsp10 represents an attractive target for anti-Corona-
virus drug discovery. Specific molecules or peptides targeting
the described nsp10 surface and inhibiting the interaction with
nsp14 and nsp16 could be developed to reduce or preventCoro-
navirus replication (66). Because nsp10 is well conserved
among coronaviruses, such compounds could then be used for
treatment or in a prophylactic approach to preventMERS-CoV
infection, possible outbursts of SARS-CoV, or any other newly
emerging lethal Coronavirus.
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